For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 42,361,879 | |||
| General and administrative | 15,801,686 | |||
| Change in estimate for legal contingencies | 0 | |||
| Income from insurance recovery | 0 | |||
| Total operating expenses | 58,163,565 | |||
| Operating loss | -58,163,565 | |||
| Interest expense | 0 | |||
| Interest income | 1,883,903 | |||
| Gain from asset sale | 360,750 | |||
| Other expense | -502 | |||
| Total other (income) expense, net | 2,244,151 | |||
| Loss before income taxes | -55,919,414 | |||
| Provision for income taxes | 5,400 | |||
| Net loss | -55,924,814 | |||
| Basic EPS | -1.41 | |||
| Diluted EPS | -1.41 | |||
| Basic Average Shares | 39,662,664 | |||
| Diluted Average Shares | 39,662,664 | |||
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)